A 522 order is a question, not a verdict
Recalls and warning letters are the signals every monitor watches. Section 522 of the FD&C Act carries an earlier, quieter one: FDA can order a manufacturer to study a device already on the market, because the agency has a safety question it cannot yet answer. The order is not a finding of harm. It is a question, filed in a public database updated every Sunday.
By Connor Griggs — Regulatory & Quality Strategist
The signals a portfolio watch is built around are the ones that arrive as verdicts: a recall, a warning letter, a classification change. Each one is FDA having already decided something. There is an earlier signal that arrives as a question instead, and most monitoring never reads it — a Section 522 postmarket surveillance order, FDA telling a manufacturer to go study a device that is already on the market, because the agency has a concern it cannot yet resolve from what it has.
The authority, and the trigger
Section 522 of the Federal Food, Drug, and Cosmetic Act — codified at 21 U.S.C. § 360l and implemented by 21 CFR Part 822 — lets FDA order postmarket surveillance of a class II or class III device that meets any one of four criteria: its failure would be reasonably likely to have serious adverse health consequences; it is implanted in the body for more than a year; it is life-supporting or life-sustaining and used outside a user facility; or it is expected to have significant use in pediatric populations. The order is issued device by device, when a specific question about that device type comes up. It is not a penalty and not a finding that the device is unsafe. It is FDA saying, on the record, that it has a question the existing evidence does not close.
What the order sets in motion
Once FDA issues a 522 order, the manufacturer has 30 days to submit a surveillance plan and must begin surveillance within 15 months. FDA can require the study to run up to 36 months— longer for devices with significant pediatric use, where the question is how the device affects growth and development over time. The order names the device, the question, and the clock. It is a multi-year commitment attached to a product, visible from the day it posts.
Where it is visible
FDA keeps the orders in a public 522 Postmarket Surveillance Studies Database, searchable by manufacturer, by device name, or by the 522 order number, and it refreshes that database every Sundaywith new orders, revised study parameters, and status changes. It is small, public, and updated on a fixed cadence — and it sits outside the four feeds this pipeline ingests. FDA Radar reads the Federal Register, warning letters, and openFDA’s recall and 510(k) endpoints; a 522 order appears in none of them. Watching it is a manual check, which is exactly why it is worth naming: a real, standing signal that a firehose-shaped monitor will never surface for you.
Why an operator should care
A 522 order is an early read on where FDA’s attention is turning for a whole device type — often before any recall, sometimes without one ever following. If the order names your product code, or the product code of a predicate you cited, it tells you the agency has an open question about that category and has committed years of a competitor’s data to answering it. That is context worth having the week it posts, not the quarter a recall might. What it does nottell you is that the device is unsafe, or that your own device shares the problem — the order is the question, and the study is what will, eventually, produce the answer.
The practice
Add the 522 database to the short list of sources you read by hand on a weekly rhythm, filtered to the product codes in your portfolio and the ones your clearances lean on. Read a new order as a flag to watch that device type more closely, not as a conclusion about any device in it. Whether an order against a neighboring device implicates your own is a judgment for a regulatory professional weighing the specific question FDA asked against your specific device — regulatory intelligence and method, never regulatory advice.
Primary sources
- 21 U.S.C. § 360l — Postmarket surveillance (FD&C Act § 522)
- eCFR — 21 CFR Part 822, Postmarket Surveillance
- FDA — 522 Postmarket Surveillance Studies Program
- FDA — 522 Postmarket Surveillance Studies Database (accessdata.fda.gov)
- FDA — Postmarket Surveillance Under Section 522 (guidance)
- FDA Radar — what we monitor and how often
Regulatory intelligence, not regulatory advice. This post describes method and published FDA records as of its date; decisions about a specific device belong with your regulatory professional.